Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
- Author(s)
- Lim, AM; Porceddu, S; Rischin, D;
- Details
- Publication Year 2025-08-15,Volume 32,Issue #8,Page 459
- Journal Title
- Current Oncology
- Publication Type
- Editorial
- Abstract
- Despite cutaneous squamous cell carcinoma (CSCC) being the second most common skin cancer worldwide, there were no approved systemic therapies for patients with unresectable and/or metastatic disease prior to the advent of anti-programmed cell death protein-1 (anti-PD1) agents cemiplimab and pembrolizumab [...].
- Publisher
- MDPI
- Keywords
- Humans; *Carcinoma, Squamous Cell/drug therapy/pathology; *Antibodies, Monoclonal, Humanized/therapeutic use/pharmacology; *Skin Neoplasms/drug therapy/pathology; *Antineoplastic Agents, Immunological/therapeutic use; Chemotherapy, Adjuvant; Male
- Department(s)
- Medical Oncology; Radiation Oncology
- Publisher's Version
- https://doi.org/10.3390/curroncol32080459
- Open Access at Publisher's Site
https://doi.org/10.3390/curroncol32080459- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-09-09 04:09:12
Last Modified: 2025-09-09 04:09:23